Kadimastem Ltd

KDST

IL0011284614

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 07:24:09 2024-04-25 am EDT			5-day change	1st Jan Change
494.7 ^ILa	+1.33%		+7.17%	-16.58%

Mar. 28	Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	MT

Kadimastem Ltd. Announces Resignation of Eynat Tsafrir, Independent Director

June 04, 2017

Eynat Tsafrir, an independent director at Kadimastem Ltd. announced her resignation June 4, 2017.

Latest news about Kadimastem Ltd

Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	Feb. 28	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	Feb. 27	CI
Kadimastem Plans Listing on Nasdaq Through Merger	Feb. 18	CI
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	Nov. 07	CI
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor	23-10-15	CI
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Kadimastem Ltd announced that it expects to receive ILS 3.53 million in funding	17-07-06	CI
Kadimastem to Launch Clinical Trial in ALS Patients Upon Approval from the Hadassah Hospital IRB	17-06-22	CI
Kadimastem Receives Approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the Phase 1/2A Clinical Trial in Als Patients	17-06-21	CI
Kadimastem Ltd announced that it expects to receive ILS 2.13 million in funding	17-06-06	CI
Kadimastem Ltd. Announces Resignation of Eynat Tsafrir, Independent Director	17-06-04	CI
Kadimastem Ltd announced that it expects to receive ILS 1 million in funding	17-03-27	CI
Kadimastem Announces Granting a Patent in the US for Treatment of Neurodegenerative Diseases	17-03-16	CI
Kadimastem Ltd. announced that it expects to receive ILS 2.7 million in funding	17-01-22	CI
Kadimastem Ltd. announced that it expects to receive ILS 2.5 million in funding	16-11-07	CI

Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KADIMASTEM LTD	-16.58%	5.44M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B